Optimi Health Completes Commercial Psilocybin Production for Australian Market & Global Trials
Summary
Optimi Health Corp. announced the completion of a GMP production run of 5mg psilocybin capsules, which are already prescribed commercially in Australia and will support upcoming clinical trials in the US and Europe.
Key Events
-
Commercial Psilocybin Production Completed
Optimi Health completed a GMP production run of its 5mg psilocybin finished drug product, manufactured entirely in-house under its Health Canada Drug Establishment Licence.
-
Supply to Australian Market
The finished psilocybin capsules are already prescribed commercially for treatment-resistant depression in Australia, with an updated bottling configuration for improved ease of use.
-
Global Clinical Trial Supply
Additional product from this production run is earmarked to support upcoming clinical research in the United States and clinical trials in Europe across various indications.
-
Significant Production Capacity
The company's facility is authorized to hold up to 20 kilograms of psilocybin and approximately 2,000 kilograms of biomass, providing commercial-scale supply capability.
Analysis
This filing confirms Optimi Health's ability to commercially produce and supply its 5mg psilocybin finished drug product, a critical step for a pharmaceutical manufacturer. The product is already being prescribed in Australia, leveraging recent regulatory changes, and will also support future clinical research, demonstrating the company's dual market strategy and operational execution following a recent capital raise.
At the time of this filing, OPTH was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $3.00 to $8.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.